These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 26661842)
1. Interleukin-2 receptor antagonist immunosuppression and consecutive viral management in living-donor liver transplantation for human immunodeficiency virus/hepatitis C-co-infected patients: a report of 2 cases. Maki H; Kaneko J; Akamatsu N; Arita J; Sakamoto Y; Hasegawa K; Tanaka T; Tamura S; Sugawara Y; Tsukada K; Kokudo N Clin J Gastroenterol; 2016 Feb; 9(1):32-7. PubMed ID: 26661842 [TBL] [Abstract][Full Text] [Related]
2. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314 [TBL] [Abstract][Full Text] [Related]
3. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946 [TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Bräu N Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B; J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005 [TBL] [Abstract][Full Text] [Related]
6. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
7. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis]. Park JI; Choi KM; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Chung YH; Lee YS; Suh DJ Korean J Hepatol; 2007 Dec; 13(4):543-55. PubMed ID: 18159152 [TBL] [Abstract][Full Text] [Related]
8. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA; Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784 [TBL] [Abstract][Full Text] [Related]
9. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387 [TBL] [Abstract][Full Text] [Related]
10. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy. Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330 [TBL] [Abstract][Full Text] [Related]
11. HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin. Feijoo J; Eirea M; Limeres J; Abeleira M; Ramos I; Ocampo A; Diz P Oral Dis; 2014 Apr; 20(3):313-8. PubMed ID: 23607445 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. Reiberger T; Rasoul-Rockenschaub S; Rieger A; Ferenci P; Gangl A; Peck-Radosavljevic M Eur J Clin Invest; 2008 Jun; 38(6):421-9. PubMed ID: 18489402 [TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM; J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748 [TBL] [Abstract][Full Text] [Related]
15. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853 [TBL] [Abstract][Full Text] [Related]
16. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin. Selvapatt N; Habibi MS; Brown A J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248 [TBL] [Abstract][Full Text] [Related]
17. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft. Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Peytavin G; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC AIDS; 2013 Oct; 27(16):2655-7. PubMed ID: 23939241 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C; JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915 [TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. Bräu N J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419 [TBL] [Abstract][Full Text] [Related]
20. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J; PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]